Celluris

Executive Summary

Celluris is a pioneering biotechnology company headquartered in Basel, Switzerland, with a strategic operational footprint in Brazil, positioning it as the first Latin American developer of personalized CAR-T cell immunotherapies. Founded in 2019, the company focuses on tailoring advanced cell therapies for both hematological malignancies and solid tumors, aiming to address critical unmet needs in oncology. By leveraging its unique geographic presence and a robust pipeline of proprietary constructs, Celluris seeks to democratize access to cutting-edge CAR-T treatments in emerging markets while maintaining a competitive edge in the global cell therapy landscape. The company's key differentiators include its dual-continent R&D and manufacturing strategy, which combines Swiss precision with Brazilian cost efficiency and regulatory agility. Although still in the preclinical to early clinical stage, Celluris is advancing toward first-in-human trials for its lead candidates. With a strong intellectual property portfolio and collaborations with academic centers, the company is well-positioned to capitalize on the growing demand for personalized cancer therapies. However, as a private, early-stage entity, execution and financing risks remain. If successful, Celluris could become a regional leader in cell therapy and an attractive partner for larger pharma.

Upcoming Catalysts (preview)

• Q4 2026IND/CTA Filing for Lead CAR-T Candidate65% success
• Q2 2026Series B Funding Round Announcement70% success
• Q2 2027First Patient Dosed in Phase 1 Trial50% success